Anavex Life Sciences Corp (OTCMKTS:AVXL) appointed Harald Hampel, MD, PhD, MSc, MA, to its Scientific Advisory Board. An internationally renowned expert on Alzheimer’s disease and associated neurodegenerative diseases, Dr. Hampel is AXA Research Fund Chair and Professor at Marie Curie University and Sorbonne Universities’ Pierre in Paris.
The AXA-UPMC Chair is hosted within the ‘Institute for Memory and Alzheimer’s Disease’, a reference facility for Alzheimer’s disease and other neurodegenerative problems, and affiliated with a pioneer neuroscience institution, known as the Brain and Spine Institute, and the Pitié-Salpétrière University Hospital.
Christopher U. Missling, PhD, the CEO and President of Anavex, said that they are thrilled to welcome Hampel in the Scientific Advisory Board. He has performed over fifty clinical studies in the past twenty years and is famous as a pioneer researcher who has advanced international programs aimed on Alzheimer’s treatment, diagnosis and the advancement of imaging and biological biomarkers, including his work as AXA-UPMC Chair. It intends to enhance early detection at the preclinical silent stage before the visibility of any clinical symptoms and signs.
The CEO added that they believe Hampel’s vast knowledge of Alzheimer’s disease, his interest and experience in drug development, and focus on early diagnosis, intervention and detection complement Anavex’s therapeutic approach and provide considerable significant value as they advance ANAVEX 2-73 drug through the clinic.
The expert speak
On his new role Dr. Hampel said that he is impressed with Anavex and the lead candidate drug ANAVEX 2-73, which demonstrated promising interim clinical results from Phase 2a Alzheimer’s study. The company boasts an impressive team of scientific and business leaders, which Dr. Hampel is delighted to join.
Anavex Life Sciences Corp (OTCMKTS:AVXL) broke above the extreme short term range established in the previous three sessions but failed to protect the gains and finally ended the first trading session of the week with a small loss of 1.15%. The volume pattern retained its low degree as the volume of the day at 1.4 million against the daily average of 2.2 million showed perfectly. The stock has been trading in the wide band of $1.00-$1.70 for the last few weeks and unless either of the boundaries is breached in a firm manner, no real trending or directional move can be expected.